Alliance Calls on DEA to Rescind or Revise Telemedicine Rule

The Alliance appreciates the DEA’s forward movement on telemedicine prescribing of controlled substances policy. However, the Alliance continues to be concerned to see language in the proposed rulemaking mandating in-person visits as this is not an appropriate guardrail for a telehealth service. Similarly, restricting the geography in which telemedicine can be offered undermines the value [...]

2025-03-19T11:15:27-04:00March 19th, 2025|

Telehealth and Outpatient Utilization: Trends in Evaluation and Management Visits Among Medicare Fee-For-Service Beneficiaries, 2019-2024

medRxiv: Telehealth and Outpatient Utilization: Trends in Evaluation and Management Visits Among Medicare Fee-For-Service Beneficiaries, 2019-2024 Prior to the pandemic, telehealth accounted for just 0.1% of monthly E&M visits but surged to 41.0% in April 2020 before stabilizing between 5.7% and 7.0% in 2023-2024. The average monthly E&M visit rate per 1,000 FFS beneficiaries [...]

2025-03-11T11:27:32-04:00March 6th, 2025|
Go to Top